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ABSTRACT 
 
Traditional medicine has been a fertile source of revealing lead novel molecules which 
are then subjected to investigations using the techniques of the modern drug discovery. 
There are a number of conventional drugs that originate from plants, such as aspirin 
(from willow bark), digoxin (from foxglove), quinine (from cinchona bark), and 
morphine (from the opium poppy). The aim of the present work was to evaluate the 
possible toxic effects of the dried roots of Asparagus laricinus extracts using Sprague 
Dawley rats as animal models. In this study we investigated the use of Asparagus 
laricinus roots extracts for novel anticancer drug development, specifically looking at 
the safety and toxicology. Previous in vitro studies on Asparagus laricinus extracts 
have demonstrated anticancer activity against three human cell lines, namely, breast 
MCF7, renal TK10 and melanoma UACC62. These necessitated further studies on 
Asparagus laricinus extracts, such as toxicity, adverse effects investigations as well 
as in vivo biological studies using animal models. The objectives of the study was to 
evaluate variations in serum biochemical parameters, investigate possible deviations 
in haematological parameters, and also to assess histopathological variations on the 
liver, kidneys and spleen tissues of animals exposed to aqueous and ethanolic 
extracts of Asparagus laricinus roots.  
 
The study was conducted at the Animal Research Unit at the University of the Free 
State, Bloemfontein, South Africa. Written approval for the final version of the protocol 
was obtained from the Interfaculty Animal Ethics Committee of the Faculty of Health 
Sciences at the University of the Free State. The dried plant roots were pulverized, 
10g soaked in ethanol or distilled water and agitated for 72 hours at 120 rpms. The 
supernatant was filtered and the ethanol removed completely under vacuum. The 
aqueous sample was lyophilized to obtain dried powdered material. The powdered 
plant material was dissolved in distilled water to prepare 2%, 10% and 20% 
concentration. The material was also dissolved in ethanol and different concentrations 
were obtained by varying the volumes of the solution administered. 
 
The study population consisted of a total of 54 Sprague Dawley rats (weighing 
between 180g and 250g), both male and female, obtained from the above research 
unit. The animals were divided into two groups of 24 and 30 rats for aqueous and 
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ethanolic extracts, respectively. The aqueous group was further divided into four 
subgroups of 6 rats which were exposed to 2%, 10% and 20% extracts and the control  
group (unexposed). The ethanolic group was divided into five subgroups of 6 rats 
which were exposed to increasing doses of 50, 100, 200 and 400mg/kg/day extracts 
and the last group served as controls (unexposed). The aqueous extracts were 
administered to the three subgroups for eight weeks ad libitum while the control group 
was exposed to tap water. Ethanol extracts were administered daily over a period of 
two weeks through gavage and the control group was administered water through 
gavage as well. Blood samples were collected, animals were sacrificed and 
organs/tissues excised for histological assessment. 
 
Biochemical and haematological tests were selected as indicators of the damage to 
the tissue of organs, including the liver, kidney and spleen. A significant difference 
(p<0.05) was observed for platelets with the ethanol extract at a dose of 50g/kg/day. 
There were no statistical differences between the treatment groups and controls with 
regard to the rest of haematological variables and selected biochemical tests. 
Comparison of the controls (n=6) and treatment groups (n=6) revealed an average 
median change in weight of slightly above 50g over the entire eight-week period of 
experimentation with aqueous extracts. A significant difference (p<0.05) was observed 
for both haemoglobin and blood urea nitrogen results with the 20% water extract. 
There were no statistical differences between the treatment and control groups with 
regard to the rest of haematological variables and selected biochemical tests. 
Histological evaluation could not reveal any pathological changes in both the aqueous 
and ethanolic extracts across all levels of dosage. 
 
The main purpose of the study was to establish whether Asparagus laricinus has any 
toxic or adverse effects on the tissue and organs of animal models. This was done by 
evaluating hepatotoxicity, nephrotoxicity, spleen and vascular damage to the animals. 
Dose-response assessment of the effect of the extract was done by analysis of the 
blood and tissue samples collected at the end of the research. Biochemical and 
haematological results could not show any patterns in abnormalities although we 
observed statistically significant results on few parameters. Histologically, no 
pathological changes were observed. In conclusion, we summarize that the 
toxicological evaluation of Asparagus laricinus extracts may be considered relatively 
© Central University of Technology, Free State
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free of toxicity when given orally, as it did not cause death, damage or inflammation to 
the tissues, nor produced any remarkable biochemical and haematological adverse 
effects in both the male and female Sprague Dawley rats. 
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CHAPTER 1 
 
INTRODUCTION 
 1.1 Background  
Traditional medicine is the sum total of the knowledge, skills, and practices based on 
the theories, beliefs, and experiences indigenous to different cultures, whether 
explicable or not (World Health Organization 2001; 2002). It is used in the 
maintenance of health as well as in the prevention, diagnosis, improvement or 
treatment of physical and mental illness (World Health Organization 2001; 2002). 
Traditional systems in general have had to meet the needs of the local communities 
for many centuries. China and India, for example, have developed very sophisticated 
systems such as acupuncture and ayurvedic medicine. Traditional medicine is 
generally available, affordable, and commonly used in large parts of Africa, Asia, and 
Latin America. 
 
Indigenous plant resources are often the source of medicine, nutrients and vitamins, 
or subsistence income available to the poorest in society (Shackleton et al., 1995). It 
is estimated that more than 80% of the world’s population utilize plants as their primary 
source of medicinal agents (Cordell, 1995). Moreover, almost 65% of the world’s 
population rely on medicinal plants for their primary health needs (Shanley & Luz, 
2003; Calixto, 2005 ; Heibatullah et al., 2012). Estimates by the World Health 
Organisation (2008) state that about 80% of Africa’s population rely on medicinal 
plants to totally or partially meet their health care needs (Addae-Mensah, 1992). 
 
Sixty percent of South Africans subscribe to traditional medicine (van Wyk et al., 1997) 
and there are over 300 000 traditional healers (Flint & Payne, 2013) which support ‘a 
multi-million dollar hidden economy’ (Cunningham, 1982; Mander & Le Breton, 2005) 
extending into neighbouring countries (Marshall, 1998). Traditional medicine is an 
integral part of the South African cultural life, a position that is unlikely to change to 
© Central University of Technology, Free State
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any significant degree in years to come (Brandt et al., 1995). In Southern Africa, the 
use and trade of traditional medicine is not restricted to rural areas (Williams et al., 
1997). In Soweto, near Johannesburg, approximately 85% of the population consult 
traditional healers regularly (Gelfand, 1993). In the KwaZulu-Natal province (South 
Africa), approximately 80% of the population seeks medical advice from traditional 
healers, in preference  or in addition to modern medicine. 
 
Traditional medicine has been a fertile source for revealing novel lead molecules, 
which are then subjected to investigation using the techniques of the modern drug 
discovery (Balunus & Kinghorn, 2005). Reports indicate that medicinal plants possess 
bioactive compounds, which are responsible for many therapeutic effects (Singh et al, 
2000). There are a number of conventional drugs that originate from plants, such as 
aspirin (from willow bark), digoxin (from foxglove), quinine (from cinchona bark), and 
morphine (from the opium poppy).  
 
In fact, almost 122 drugs were discovered from 94 plant species through 
ethnobotanical leads (Fabricant & Farnsworth, 2001). Interestingly, of the 877 novel 
medicines that were developed in the period 1981-2002, 6% were natural products, 
27% were derivatives of natural products and 16% were synthetics developed on the 
model of a natural product (Newman et al., 2003). This demonstrates that nature is an 
important source for developing novel leads for medicines (Cragg & Newmann, 2005). 
Even when new chemical structures are not found during drug discovery from 
medicinal plants, known compounds with new biological activity can provide important 
drug leads.  
 
Modern isolation and screening technologies have enhanced the search for new lead 
molecules and increased interest in folk medicinal plant extracts by drug companies 
(Balunus & Kinghorn, 2005). Simultaneously, the enthusiasm for medicinal herbs and 
natural products have increased among the general public. There may be some safety 
concerns with traditional remedies, although they have been utilized in practice for 
hundreds of years. 
 
Frequently used plants in traditional medicine are assumed safe, due to their long-
term use (Elgorashi et al., 2002), and are considered to have no side effects because 
© Central University of Technology, Free State
3 
 
they are ‘natural’ (Popat et al., 2001). This safety is based on their long-term usage in 
the treatment of diseases according to knowledge accumulated over centuries. This 
concept is largely circumstantial and it is important to determine the toxicology of plant 
extracts, especially those that are used frequently over long periods. Contrary to 
perceptions and general beliefs regarding the safety of medicinal plants, recent 
scientific research has shown that many plants used as food, or in traditional medicine, 
are potentially toxic, mutagenic and carcinogenic (Schimmer et al., 1988; Higashimoto 
et al., 1993; Schimmer et al., 1994; Kassie et al., 1996; De Sã Ferrira & Ferrão Vargas, 
1999; Elgorashi et al., 2003; Marques et al., 2003). 
 
The fact that medicinal plants may be toxic, mutagenic and carcinogenic is a clear 
warning that the consumption of medicinal plants without studies of efficacy and safety 
might be detrimental to our health. The danger is that continuous consumption may 
result in several side effects and complications that may affect different tissues and 
organs. Although consumption of such medicines may damage various tissues, the 
liver and kidneys are prime targets simply because they are involved in the 
degradation and excretion of a myriad of chemical compounds.  
 
Mapanga & Masubayane (2010) have demonstrated the association between the use 
of medicinal plants for different disorders (including diabetes mellitus) with renal 
damage. There is still a lack of detailed documentation on the use of medicinal plants 
in South Africa. This is becoming an urgent issue, based on the fragility of traditional 
knowledge transmitted orally and the rapid pace of urbanisation and acculturation in 
this country (van Wyk et al., 1997). The informal (oral) traditional medical systems of 
the Khoi-San, the Nguni and the Sotho-speaking peoples of South Africa have not yet 
been systemized (van Wyk et al., 1997). 
 
Formal and informal (oral-tradition) systems of medicine exist together in South Africa, 
the first dating back only 300 years with the influx of European settlers and the latter 
possibly to Paleolithic times (van Wyk et al., 1997).  
 
In South Africa, and Africa as a whole, the evaluation and recognition of traditional 
medicine aims to improve its efficacy, safety, availability and wider application at low 
cost (Fennel et al., 2004). Despite the range of medicinal plants used and the rich 
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biodiversity of South Africa, only a relatively small number of plant species have been 
scientifically validated (Springfield et al., 2005). 
 
Despite deriving from foundations in the past, traditional medicine is not a static 
system, but is dynamic and adaptive. Although it reflects the value and perceptions of 
the people, it is under pressure from the introduction of the Western culture. The 
introduction of modern medicines and practices (including standardization of doses) 
as well as other socio-economic development processes (such as medical records 
and access to medical aid schemes) can improve the application of traditional healing. 
 
Although Le Grand & Wondergem (1989) proposed that many users could benefit from 
the dissemination of existing knowledge, this has become a controversial subject. 
Intellectual property rights and the exploitation of developing countries’ natural 
resources have become the focus of ethnobotany in the past few years. 
 
Only a few clinical studies have been performed to verify the potency of traditional 
remedies against common diseases (Springfield et al., 2005). However, plant-derived 
natural products provide an interesting source for isolating and screening potent 
molecules to combat inflammatory diseases (Shale et al., 1999; Vigorita et al., 2001; 
Ojewole et al., 2007), hypertension (Kavitha et al., 2006) and cancer (Kucuk  Guzel et 
al., 2006; Angelo & Edzard, 2009; Mashele & Kolesnikova, 2010). Several promising 
molecules have been identified recently, but there are still hurdles to overcome before 
they can become accepted as modern drugs. 
 
There have been many validations of traditional remedies through scientific research, 
and the use of ethnomedical information has also contributed to health care worldwide 
through the isolation of bioactive compounds for direct use in medicine. The adverse 
effects of widely used plants are not well-documented in the literature. Based on their 
long-term use by man, one might expect the plants used in traditional medicine to have 
a low toxicity (Heibatullah et al., 2012). 
However, recent investigations have indicated that many plants used as food or in 
traditional medicine have mutagenic effects in in vitro assay, which raises concerns 
about the potential mutagenic hazards resulting from the long-term use of medicinal 
plants (McGaw et al., 2000; Fabricant & Farnsworth, 2001). 
© Central University of Technology, Free State
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1.2 Problem statement 
 
Although treatments are targeted at tissues and organs in order to reduce morbidity 
and prevent mortality in the population, very often they lead to complications and 
adverse effects, especially when used over long periods. Almost all modern treatments 
have some side-effects which might be detrimental to the health of patients. These 
include, amongst others, chemotherapy, radiation therapy and surgery for the 
treatment of cancer. 
 
In this study we were looking at the possibility of utilizing medicinal plants for novel 
anticancer drug development, specifically looking at the safety and toxicology of 
Asparagus laricinus. Previous in vitro studies on Asparagus laricinus extracts have 
demonstrated anticancer activity against three human cell lines, namely, breast MCF7, 
renal TK10 and melanoma UACC62 (Fouche et al., 2006; Mashele & Kolesnikova, 
2010). These necessitate further studies on Asparagus laricinus extracts, such as 
toxicity, adverse effects investigations as well as in vivo biological studies using animal 
models.  
 
Asparagus laricinus is monogeneric family, which was previously included within the 
Liliaceae family (Brummitt, 1992). It belongs to the family of Asparagaceae, a monocot 
and a member of the order Asparagales, that possess great diversity throughout Africa 
and especially in South Africa. Asparagus (Asparagaceae) is highly diverse with 
hermaphroditic and unisexual taxa, a variety of growth forms (herbs, shrubs, and 
vines), and vegetative morphology (phylloclade morphology, presence or absence of 
spines) (Dahlgren et al.,1985). 1.3 Justification of the study 
 
Although Asparagus laricinus extracts have demonstrated anticancer activity in vitro; 
in vivo toxicity studies were never performed. Furthermore, antimutagenic activity in 
animal models also needs to be investigated. This study will pave a way to the next 
level which will be in vivo analysis of the extracts on animal models, which may 
probably lead to preclinical research; as well as phases I, II, and III of clinical trials in 
future. 
© Central University of Technology, Free State
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1.4 Research aims and objectives 
 1.4.1 Aim of the Study 
 
The aim of the present work was to evaluate the possible toxic effects of the dried 
roots of Asparagus laricinus extracts using Sprague-Dawley rats as animal models.  1.4.2 The objectives of this project 
 
To investigate the toxicity of Asparagus Laricinus extracts by: 
1. Evaluating variations in serum biochemical tests after exposing the rats to different 
concentrations of extracts in different solvents. 
2. Investigating variations in haematological parameters after exposing the rats to 
different concentrations in different solvents. 
3. Assessing histopathological variations of the liver, kidney and spleen tissues of rats 
exposed to different concentrations in different solvents. 
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CHAPTER 2  LITERATURE REVIEW  2.1 Overview of cancer 
 
One of the most prominent diseases in humans today is cancer. Cancer is a generic 
term used for a large group of diseases that can affect any part or organs of the body. 
It is also referred to as malignant tumours or neoplasms. It is a group of diseases 
characterized by uncontrolled cell growth beyond their usual boundaries; which can 
invade adjoining parts of the body and spread to other organs. The process of 
spreading to other organs is referred to as metastasis and is the major cause of death 
from cancer (Murthy et al., 1990). 
 
Cancer arises from a single cell. The transformation from normal to a tumour is a 
multistage process, typically from pre-cancerous to malignant tumours. The changes 
are the results of the interaction between an individual’s genetic makeup and three 
categories of external or environmental factors, viz.: 
• biological carcinogens, such as viral, bacterial or parasitic infections, 
• chemical carcinogens, e.g. asbestos, aflatoxin, components of smoke or 
arsenic; and 
• physical carcinogens such as ultraviolet and ionizing radiation. 
 
Generally, cancer begins after a mutational episode in a single cell and then it 
progressively transforms to malignancy in multiple stages through sequential 
acquisition of additional mutations (Khan & Pelengaris, 2006). In view of the fact that 
these initial events are the underlying causes of the whole progression of 
carcinogenesis, their inhibition would therefore be an efficient preventive measure 
(Bertram, 2001). 
 
© Central University of Technology, Free State
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2.2 Phases in development of cancer  
Cancer develops in several phases, depending on the type of tissue affected. 
Typically, these phases are: dysplasia, cancer in situ, localized invasive cancer, 
regional lymph node involvement, and distant metastases (WHO 2002). The first 
indication of abnormality is a change in the character of cells, known as dysplasia. The 
term “carcinoma in situ” is used when microscopic examination discloses cells with 
certain characteristics of cancer, that is, changes in the cell nuclei, but with no 
penetration of the underlying membrane that holds them in the tissue of origin. When 
the abnormal cell growth reaches areas underlying the tissue of origin, the cancer is 
regarded as invasive. With further growth, there is increasing invasion and destruction 
of adjacent tissues. Often, the cancer extends to the regional lymph nodes that drain 
the area. Cancer cells may also spread through the blood or lymphatic system to affect 
other organs (distant metastases). 
 
With sufficient multiplication of abnormal cells, the cancer becomes apparent to the 
individual or to the physician. It commonly takes the form of a lump that may be seen 
or palpable in the organ involved, for example skin, breast, or prostate. Sometimes, 
even before detection, the cancer will have spread to lymph nodes or, if rapidly 
progressive, will have already caused detectable distant metastases. Figure 2.1 
summarizes processes or stages in cancer development.  The growth of the cancer 
can involve blood vessels and cause bleeding, which will be apparent if the cancer 
reaches part of an organ that is in direct or indirect contact with the exterior. For 
example, there may be blood in the sputum from lung cancer, blood in the stools from 
bowel cancer, or blood in the urine from bladder cancer. The growth of a cancer may 
also cause functional disturbances. For example, cancer of the brain may give rise to 
neurological symptoms and signs.  
 
 
 
 
 
Figure 2.1 Typical phases or stages of cancer development. 
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invasive 
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2.3 Burden of cancer 
 
According to the WHO, cancer is the leading cause of death worldwide and accounted 
for 8.2 million deaths (around 14% of all deaths) in 2012 (Globocan, 2012). The major 
causes of death are cancer of the lung, liver, stomach, breast and colorectal cancer. 
The distribution in terms of causes of mortality differs between males and females and 
also varies between developing and developed countries. Table 2.1 indicates the 
global and regional patterns of death by cause, as captured by the World Health 
Organization (2001). 
 
Cancer remains a major obstacle to the overall public health in the more developed 
regions such as Europe and North America, as indicated in  Table 2.1. More than 60% 
of the world’s total new annual cases occur in Africa, Asia and Central and South 
America. These regions account for 70% of the world’s cancer deaths (Globocan 
2012). Although cancer is not a major problem for Africa, medicinal plants found 
throughout Africa may be a solution to developed countries in terms of providing plants 
(as herbs) or in identifying novel chemotherapeutic agents in plants. 
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Table 2.1 Global and regional patterns of annual deaths, by cause, 2000 
        
 
Deaths from all 
causes(thousands) 
Deaths from 
infectious and 
parasitic diseases (%) 
Deaths 
from 
cancer (%) 
Deaths from 
circulatory 
diseases (%) 
Perinatal 
deaths (%) 
Deaths from 
injury (%) 
Deaths 
from other 
causes (%) 
World 
total 
55694 25.9 12.6 30 4.4 9.1 18 
        
More 
developed 
countries 
13594 6.1 21.6 47.9 0.7 7.9 15.9 
Less 
developed 
countries 
42100 32.3 9.8 24.2 5.6 9.5 18.7 
        
Africa 10572 61.7 5.1 9.2 5.5 7.1 11.5 
South and 
Central 
America 
3097 14.6 14.1 28.5 4.3 12.3 26.2 
North 
America 
2778 6.3 23.8 41.1 0.6 6.4 21.9 
Middle 
East 
4036 32.1 6.1 26.9 7.5 8.4 19.1 
South East 
Asia 
14157 29.9 8.1 28.9 7.1 9.7 16.4 
Western 
Pacific 
11390 10.6 18.6 31.2 2.8 10.7 26.1 
Europe 9664 5.4 19.8 51.5 0.8 8.5 14.1 
Source: The World Health Report 2001. WHO, Geneva 
 
The following tables indicate the top 20 cancer deaths by cause for the population of 
South Africa for the year 2000. Table 2.2 clearly demonstrates that tracheal, bronchial 
and lung cancers are the major causes of death (16.5%) in the overall population, 
followed by oesophageal (13.3%) and cervical (8.3%) cancers respectively. 
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Table 2.2 Number of deaths due to different cancers in the year 2000 for South 
Africa 
All persons 
Rank Cause of Death Deaths 
1 Tracheal, Broncheal and Lung cancer 6885 
2 Oesophageal cancer 5579 
3 Cervical cancer 3498 
4 Breast cancer 3206 
5 Liver cancer 2651 
6 Colorectal cancer 2567 
7 Prostate cancer 2524 
8 Stomach cancer 2348 
9 Pancreatic cancer 1541 
10 Leukaemia 1465 
11 Mouth and Oropharyngeal cancer 1386 
12 Lymphoma 1032 
13 Laryngeal cancer 746 
14 Bone and Connective tissue cancer 707 
15 Ovarian cancer 691 
16 Bladder cancer 673 
17 Uterine cancer 638 
18 Brain cancer 527 
19 Melanoma 437 
20 Kidney cancer 427 
All cancers 41657 
(Source: Cancer Association of South Africa) 
 
Tables 2.3 and 2.4 categorize the causes of death by gender, male and female 
respectively. In Table 2.3 the picture remains the same for the number one and two 
causes of death, i.e. tracheal, bronchial and lung cancers; and oesophageal cancers 
which represent 21.9% and 16.7% of the male population respectively. Prostate 
cancer moves from the seventh position to third in the male population. 
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Table 2.3 Number of deaths due to different cancers in the year 2000 for males 
Males 
Rank Cause of Death Deaths 
1 Tracheal, Broncheal and Lung cancer 4669 
2 Oesophageal cancer 3566 
3 Prostate cancer 2524 
4 Liver cancer 1666 
5 Stomach cancer 1386 
6 Colorectal cancer 1157 
7 Mouth and Oropharyngeal cancer 985 
8 Leukaemia 818 
9 Pancreatic cancer 789 
10 Laryngeal cancer 633 
11 Lymphoma 601 
12 Bladder cancer 469 
13 Bone and Connective tissue cancer 360 
14 Brain cancer 274 
15 Kidney cancer 233 
16 Melanoma 233 
17 Non-Melanoma skin cancers 158 
18 Breast cancer 50 
All cancers 21361 
(Source: Cancer Association of South Africa) 
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In Table 2.4, breast cancer leaps from the fourth  to the first position in the female 
category. This represents 17.2% of the female population, followed by breast cancer 
(15.5%) and tracheal, bronchial and lung cancers (10.9%) in the third position. As 
mentioned earlier, Mashele & Kolesnikova (2010) have demonstrated in vitro 
antimutagenicity of Asparagus laricinus extracts against breast cancer (MCF7), which 
is the second major cause of death within the female population. 
 
Table 2.4 Number of deaths due to different cancers in the year 2000 for females 
Females 
Rank  Deaths 
1 Cervical cancer 3498 
2 Breast cancer 3156 
3 Tracheal, Broncheal and Lung cancer 2216 
4 Oesophageal cancer 2013 
5 Colorectal cancer 1410 
6 Liver cancer 986 
7 Stomach cancer 962 
8 Pancreatic cancer 752 
9 Ovarian cancer 707 
10 Leukaemia 647 
11 Uterine cancer 638 
12 Lymphoma 431 
13 Mouth and Oropharyngeal cancer 401 
14 Bone and Connective tissue cancer 331 
15 Brain cancer 253 
16 Bladder cancer 204 
17 Melanoma 203 
18 Kidney cancer 176 
19 Laryngeal cancer 114 
20 Non-Melanoma skin cancers 108 
All cancers 20296 
(Source: Cancer Association of South Africa) 
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2.4 Global cancer projections and strategies to curb escalating   numbers.  
It was projected that the annual cancer burden would rise from 14 million in 2012, to 
22 million within the next two decades. The World Health Organization 2005 also 
projected an escalation in deaths from cancer, with an estimated 9 million deaths in 
the year 2015, and 11.4 million deaths by 2030. 
 
Primary prevention measures, early detection mechanisms and cure are needed for 
Africa’s cancer burden (715,000 new cases and 542, 000 deaths in 2008), a burden 
projected to double by 2030 due to demographic changes alone. Figure 2.2 illustrates 
the escalation in deaths caused by cancer in both developed and developing countries 
throughout the globe, as projected by the World Health Organization (Globocan, 2008). 
 
 
Figure 2.2 Global cancer death projections (2008 - 2030) 
 
Currently, there is marked scientific and commercial interest in the continuing 
discovery of new anti-cancer agents from natural product sources (Kinghorn et al., 
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2003). More than 50% of drugs used in clinical trials for anticancer activity, were 
isolated from natural sources or are related to them (Newman & Cragg, 2007). Hence, 
the search for natural products to be used in cancer therapy represents an area of 
great interest in which the plant kingdom is the most important source, providing many 
anti-tumour agents with novel structures and unique mechanisms of action (Chang et 
al., 1999). 
 
Present chemotherapy cancer treatments have proved to be ineffective as a result of 
their toxicity and cells developing resistant (McWhirter et al.,1996). Many conventional 
drugs also induce genetic damage that itself can be carcinogenic (Mashele & Fuku, 
2011). A segment of the research community is thus focusing on identifying novel 
chemotherapeutic agents in plants that do not induce the destructive effects of 
conventional cytotoxic therapeutic agents. Table 2.5 below illustrates examples of side 
effects of some conventional drugs: 
 
Table 2.5 Excerpt of Table of Major Chemotherapy Drugs and Hormones (modified from 
Mora & Potts, 2003) 
 
Name and Use 
  
Common Side Effects 
  
Occasional Side Effects 
  
Aminoglutethimide (Cytrdren, 
Elitpen).  An aromatase 
inhibitor used in adrenal and 
prostate cancers. May be used 
as medical adrenalectomy in 
breast cancer. Given as a tablet. 
  
Skin rash with fever, 
sluggishness and 
tiredness (usually goes 
away slowly within 4 to 
6 weeks after treatment 
is finished). 
  
Dizziness, swelling of face, 
weight gain, leg cramps, 
fever, chills and sore throat, 
loss of appetite, mild nausea 
and vomiting, leg cramps. 
  
Cyclophosphamide(Cytoxan, 
Neosar, Endoxan)  An 
alkylating agent used in 
lymphomas and Hodgkin’s 
disease, myeloma, 
neuroblastoma, retinoblastoma, 
sarcomas, Wilms’ tumor, 
cancers of the ovary, breast, 
prostate, head and neck, lung, 
  
Nausea, vomiting, loss of 
appetite, loss of 
hair.  (The patient) needs 
to drink extra liquids to 
prevent bladder 
problems. If (the patient) 
misses a dose, they 
should not double the 
  
Blood in urine, pain when 
urinating, black tarry stools, 
fever, chills, nasal stuffiness 
and sore throat, cough and 
shortness of breath, dizziness, 
confusion, fast heartbeat, 
sterility (may be temporary), 
skin darkening, metallic taste 
during injection, blurred 
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Name and Use 
  
Common Side Effects 
  
Occasional Side Effects 
bladder, cervix, stomach and 
uterus. Given IV or as a tablet. 
next dose, but should 
talk with one’s doctor. 
vision, cataract, second 
cancers (leukemia, bladder). 
  
Doxorubicin (Adriamycin, 
Rubex, Adriamycin RDF, PFS 
or MDV) An antitumor 
antibiotic used in leukemias, 
lymphomas, Wilm’stumor, 
neuroblastoma, multiple 
myelomas, sarcomas, cancers 
of the breast, ovary, bladder, 
thyroid, stomach, cervix, 
endometrium, liver, esophagus, 
head and neck, pancreas, 
prostate, testes and lung. Given 
IV. 
  
Nausea and vomiting, 
red urine (usually lasts 
one or two days after 
each dose), hair loss, loss 
of appetite, heart 
problems. 
  
Mouth sores, darkening of 
soles, palms or nails, may 
reactivate skin reactions from 
past radiation, fever, chills 
and sore throat, diarrhea, eye 
problems, fast or irregular 
heartbeat, shortness of breath, 
pain in joint, side or stomach, 
burning pain at injection site. 
  
Fluorouracil (Adrucil, 5-FU, 
5-Fluorouracil, Efudex)  An 
antimetabolite used in cancers 
of the stomach, colon, rectum, 
breast, pancreas, bladder, 
cervix, endometrium, 
esophagus, head and neck, 
liver, lung, ovary and skin. 
Usually given IV, except for 
skin, where a cream is used. 
  
Nausea, mouth sores, 
diarrhea, skin darkening 
(sensitive to sun). 
  
Mouth, tongue or lip sores, 
hair loss, skin rash or dryness, 
vomiting, poor muscle 
coordination, swelling of 
palms and soles, nail loss or 
brittle nails, eye irritation, 
increase of tears, blurred 
vision, headache, euphoria. 
  
Methotrexate (Folex, Folex 
PFS, Mexate, Mexate-AQ, 
Abitrexate, Rheumatrex)  An 
antimetabolite used in 
choriocarcinoma, hydatiform 
mole, multiple myeloma, 
leukemia, lymphomas, 
sarcomas, cancers of the breast, 
head and neck, lung, bladder, 
brain, cervix, esophagus, 
kidney, ovary, prostate, 
stomach and testes. Given IV 
  
Mild nausea and 
vomiting, diarrhea, 
mouth sores. (The 
patient) should not take 
more or less than the 
amount prescribed by the 
doctor. If a dose is 
missed, the next dose 
should not be doubled 
and the physician should 
be consulted. 
  
Loss of appetite, stomach 
pain, yellowing of eyes or 
skin, fever, chills and sore 
throat, cough, shortness of 
breath, blood in urine or dark 
urine, hair thinning, headache, 
dizziness, blurred vision, 
drowsiness or confusion, joint 
pain, skin rash, reddening of 
skin (sensitive to sun) anemia, 
flank pain, blurred vision, 
confusion, seizures. 
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Name and Use 
  
Common Side Effects 
  
Occasional Side Effects 
most commonly, in the muscle, 
or as a tablet. 
(The patient) may need 
to drink extra liquids to 
prevent kidney problems. 
(The patient) should not 
take aspirin or other 
medicine for swelling or 
pain without first 
checking with the 
physician. 
When very high doses 
are given, it is followed 
by the drug 
leucovorincalcium to 
counteract life-
threatening side effects 
(called leucovorin 
rescue). 
  
Tamoxifen (Nolvadex, 
taxomifen 
citrate)  Anantiestrogen used in 
breast cancer. Given as a tablet. 
  
Hot flashes, vaginal 
discharge. (The patient) 
should not take more or 
less than the amount 
prescribed by the 
physician. If (the patient) 
misses a dose, she should 
not take the missed dose 
at all and should not 
double the next dose; she 
should consult with her 
doctor. The patient 
should use birth control 
while taking tamoxifen, 
but she should not take 
birth control pills since 
they may change the 
effects of the tamoxifen. 
If she should become 
pregnant while taking 
tamoxifen, she should 
consult with her 
physician immediately. 
  
Vaginal bleeding, dryness or 
itching, nausea, and vomiting, 
loss of appetite, irregular 
menstrual periods, hot 
flashes, endometriosis, bone 
and tumor pain, visual 
changes skin rash and 
itchiness, dizziness, loss of 
hair, depression, light-
headedness, confusion, fluid 
retention, headache, anemia, 
swelling of legs, loss of 
appetite, blood clots, 
increased risk of uterine 
cancer. 
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Name and Use 
  
Common Side Effects 
  
Occasional Side Effects 
  
Vincristine (Oncovin, Vincasar 
PFS, leurocristine)  A plant 
alkaloid used in leukemia, 
lymphomas, sarcomas, 
neuroblastoma, Wilms’ tumor, 
melanoma, multiple myeloma, 
cancers of the colon, rectum, 
brain, breast, cervix, ovary, 
lung and thyroid. Given IV. 
  
Hair loss, numbness or 
tingling in hands or feet. 
  
Pain in arms, legs, jaw or 
stomach, pain in testicles, 
mouth sores, fever, chills and 
sore throat, severe 
constipation, metallic taste, 
hoarseness, agitation, 
confusion, light-headedness, 
dizziness, drooping eyelids, 
jaw or joint pain, blurred or 
double vision, anemia, 
stomach cramps. 
Temodal 
Brain cancer 
Blood and bone marrow 
problems, hair loss, 
nausea vomiting, 
diarrhoea 
 
Vectibix Colorectal cancer Metabolic problems, 
blurred vision, back pain, 
hair loss, coughing, 
breathing difficulties, 
difficulty in sleeping 
 
Cisplatin 
 Ovarian, testicular and bladder 
cancer 
Neurotoxicity, deafness  
 2.5 Cancer and medicinal plants 
 
Knowledge about the medicinal value of many plants that form part of the rich 
biodiversity in South Africa is largely contained in the oral traditions of the various 
ethnic groups that constitute the indigenous people of South Africa (van der Merwe et 
al., 2001). 
 
Several medicinal plants are traditionally used in the treatment of a variety of ailments, 
including cancer in many communities of South Africa and neighbouring countries. 
Since ancient times, herbal medicine has always been one of the main components 
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of the healthcare system. Despite the range of medicinal plants used and the rich 
biodiversity of South Africa, only a relatively small number of plant species have been 
scientifically validated for safety and efficacy (Springfield et al., 2005). 
 
Traditional medicine has been a fertile source for revealing novel lead molecules, 
which are then subjected to investigation using the techniques of modern drug 
discovery (Balunus & Kinghorn, 2005). In fact, modern pharmaceutics have benefited 
from medicinal plants (Table 2.6). Although discovered through serendipitous 
laboratory observation, three of the major sources of anticancer drugs on the market, 
or completing clinical trials, were derived from North American plants used medicinally 
by Native Americans: the Papaw (Asimina spp), the Western Yew Tree (Taxus 
brevifolia), effective against ovarian cancer and the May-apple (Podophyllum 
peltatum) used to combat leukaemia, lymphoma, lung and testicular cancer (Gurib-
Fakim, 2006). 
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Table 2.6 Botanical drugs used in traditional medicine, and from which useful 
modern drugs were produced. 
Botanical names English 
names 
Indigenous 
use  
Origin Uses in 
Biomedicine 
Adhatodavasica - Antispasmodic, 
antiseptic, 
insecticide, fish 
poison 
India, Sri 
Lanka 
Antispasmodic, 
oxytocic, 
cough 
suppressant 
Catharanthusroseus Periwinkle Diabetes, fever Madagascar Cancer 
chemotherapy 
Condrodendrontomentosum - Arrow poisoning Brazil, Peru Muscular 
relaxation 
Gingko biloba Gingko Asthma, 
anthelmintic 
(fruit) 
Eastern 
China 
Dementia, 
cerebral 
deficiencies 
Harpagophytumprocumbens Devil’s 
claw 
Fever, 
inflammatory 
conditions 
Southern 
Africa 
Pain, 
Rheumatism 
Piper methysticum Kava Ritual stimulant, 
tonic 
Polynesia Anxiolytic, 
mild stimulant 
Podophyllumpeltatum May apple Laxative, skin 
infections 
North 
America 
Cancer 
chemotherapy, 
warts 
Prunusafricana African 
plum 
Laxative, ‘Old 
man’s disease’ 
Tropical 
Africa 
Prostate 
hyperplasia 
Source:  A. Gurib-Fakim / Molecular aspects of medicine 27 (2006) 1-93 
 
Interestingly, of the 877 novel medicines that were developed in the period 1981-2002, 
6% were natural products, 27% were derivatives of natural products and 16% were 
synthetics developed on the model of a natural product (Newman et al., 2003). This 
demonstrates that nature is an important source for developing novel leads for 
medicines. Even when new chemical structures are not found during drug discovery 
from medicinal plants, known compounds with new biological activity can provide 
important drug leads. 
 
Currently, over 85, or 48.6%, of drugs used in clinical trials for anticancer activity, are 
actually derived from natural products or are natural products (Newman & Cragg, 
2012). This demonstrates the rationale for the search for novel drug molecules in 
medicinal plants, especially when literature shows that plant-derived compounds have 
provided attractive possibilities for treatment strategies (Jain & Jain, 2011). 
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 2.6 Asparagus laricinus 
 
In this study Asparagus laricinus, belonging to Asparagaceae family, was investigated. 
Asparagus laricinus is a monogeneric family, which was previously included within the 
Liliaceae family (Brummitt, 1992). It belongs to the family of Asparagaceae, a monocot 
and a member of the order Asparagales, and possesses great diversity throughout 
Africa,  especially in South Africa. This plant is commonly known as Lesitwane among 
the Batswana clans in South Africa. 
 
Asparagus (Asparagaceae) is highly diverse with hermaphroditic and unisexual taxa, 
a variety of growth forms (herbs, shrubs, and vines), and vegetative morphology 
(phylloclade morphology, presence or absence of spines) (Dahlgren et al.,1985). 
The genus Asparagus comprises approximately 100 species and consists of herbs, 
shrubs and vines. 
 
Asparagus laricinus is part of the traditional medicine used in many parts of South 
Africa for the treatment of several ailments. Examples of its use include its roots for 
the treatment of tuberculosis, and its  use as a diuretic in the Khoi-San and Cape Dutch 
ethnobotany (van Wyk, 2008). In the North West province, the roots are used for 
treatment of sores, redwater, urinary infections, umblical cord inflammation and 
general ailments by Setswana-speaking people (van Der Merwe et al., 2001). The 
leaves and stem are medicinally used in South West parts of Gauteng (Dzerefos & 
Witkowski, 2001). 
 
Many of these herbs, including Asparagus laricinus, have not yet been scientifically 
assessed for their efficacy or safety to tissue or organs of recipients in vivo. Mashele 
& Fuku, (2011) showed that Asparagus laricinus polyphenol extract exhibited a dose-
dependent antimutagenic ability. The plant extract showed no mutagenic effect on all 
tested Salmonella typhimurium bacteria strains in vitro. Previous in vitro studies on 
Asparagus laricinus extracts have demonstrated anticancer activity against three 
human cell lines namely, breast MCF7, renal TK10 and melanoma UACC62 (Fouche 
et al., 2006; Mashele & Kolesnikova, 2010). 
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These cell lines were selected because of their high sensitivity to detect anticancer 
activity. Thus, investigation of traditionally used medicinal plants is valuable as a 
source of potential chemotherapeutic agents, and also to assess the safety of the 
continuous use of medicinal plants. As a result, most studies are being directed at 
popular medicine, with the aim of identifying natural products which exhibit therapeutic 
properties (Hamburger & Hostettmann, 1991). 
 
As some of the active ingredients are potentially toxic, there is a need to evaluate the 
safety of plant preparations. These necessitate further studies on Asparagus laricinus 
extracts, such as toxicity, adverse effects investigations, as well as in vivo biological 
studies using animal models. 2.7 Previous toxicology studies on medicinal plants 
 
Although plant extracts have been used in the treatment of diseases according to 
knowledge accumulated over centuries, scientific research has shown some 
substances present in these medicinal plants to be potentially toxic and carcinogenic 
(De Sã Ferrira & Ferrão,1999). Investigation of traditionally used medicinal plants is 
thus valuable on two levels: firstly, as a source of potential chemotherapeutic drugs, 
and secondly, as a measure of safety for the continued use of medicinal plants 
(Verschaeve et al., 2004). The latter is the area of concern for the researcher, since 
Asparagus laricinus has been used in folk medicine for the treatment of cancer for 
years. 
Literature does not reveal any previous toxicological studies for Asparagus laricinus 
per se, but several studies were performed on other medicinal plants used for the 
treatment of cancer. Arun & Tangpu (2006) demonstrated that Lithocarpus dealbata 
showed no mortality or any visible signs of acute toxicity, while serum biochemistry 
tests did not reveal any noticeable changes in aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), cholesterol (CHOL) and protein levels in animals. 
Toxicological studies on Moringa oleifera have indicated an absence of severe  
hepatotoxicity and organ damage, except in very high doses. The acute lethality (LD50) 
test has been found to be relatively safe with subchronic toxicity studies, eliciting no 
significant difference in sperm quality, haematological and biochemical parameters in 
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the treated rats, as compared to the controls (Isitua & Ibeh, 2003; Awodele et al., 2012; 
Ugwu et al., 2013). These studies engaged the use of laboratory experimental animal 
models to evaluate the toxicology of plant extracts. 
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CHAPTER 3 
 
RESEARCH DESIGN AND METHODOLOGY 
 3.1 Introduction 
 
Toxicology is the study of how chemical substances interact with living systems and 
affect normal processes. The information obtained from toxicological studies is utilized 
to predict safe exposure levels of chemicals. Although in vitro analysis (e.g. tissue 
cultures and organs) of toxicity is preferred, animal models are necessary to validate 
the results of non-living or in vitro tests. The in vitro tests are performed as the last 
protective step before exposure of humans and animals to potentially dangerous 
substances. The advantage of animal testing is to evaluate the effect when the entire 
system is involved, which cannot be evaluated by in vitro tests; as hormones, enzymes 
and other systemic influences are not available. 
 
In this study, Sprague Dawley rats were utilized to determine the toxicity of Asparagus 
laricinus extracts. The animals were exposed to different concentrations of ethanol 
and water extracts of Asparagus laricinus over a maximum period of eight weeks. The 
rats were sacrificed at the end of the experiment, blood collected and tissues excised 
for biochemical, haematological and histological analysis. 
 3.2 Study design 
 
A case control study that involved experimental animals, where cases were exposed 
to different concentrations of Asparagus laricinus extracts utilising water, 
dichloromethane and ethanol as solvents. Controls were not exposed to the extract 
but supplied with water, which served as placebo. 
  3.3 Study population 
 
Sprague Dawley rats of either sex were reared at the Animal Research Unit of the 
University of the Free State, Bloemfontein, South Africa. The rats were three months 
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old; weighed between 180g and 250g at the beginning of the experiment; and were 
fed with standard pelleted food. 3.4 Sample size 
 
A total of 78 Sprague Dawley rats, both male and female, obtained from the Animal 
Research Unit at the University of the Free State in 2013, were divided into 3 major 
groups which were exposed to water, ethanol and dichloromethane extracts of 
Asparagus laricinus. The three groups consisted of 24 rats for the water extract, 30 
rats for ethanol extract and 24 rats for dichloromethane extract. A total of 12 rats were 
used as controls and they were included in the numbers supplied for the water  and 
ethanol extracts. The six used for the water extract were utilised for the entire 8-week 
period, while the other six controls were used for two weeks of exposure to ethanol 
and dichloromethane extracts. 
 
The dichloromethane extract was discontinued when two rats died due to adverse 
effect after administration of the extract. Due to the adverse effects mentioned, the 
dichloromethane group was discontinued and this resulted in only 54 rats being used 
for the entire experiment.  3.5 Inclusion and exclusion criteria 
 
Rats weighing between 150g and 250g were included in the study to ensure 
homogeneity amongst the study population. 
Rats weighing above or below the above-mentioned range were excluded. 
 3.6 Ethical consideration 
 
Written approval for the final version of the protocol was obtained from the Interfaculty 
Animal Ethics Committee (Ethics number 16/2012 – Appendix A) of the Faculty of 
Health Sciences at the University of the Free State, before the extracts could be 
administered to the rats. The study was conducted at the animal facility by the 
researcher, under the guidance of personnel who are skilled and trained in the 
handling of experimental animals, and the ethical guidelines were followed at all times. 
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At the end of the study the rats were administered with Halothane (anaesthetic) and 
blood samples collected. They were finally sacrificed by administration of higher doses 
of halothane. 
 3.7 Materials  3.7.1 Plant authentication (validation) 
 
The plant was authenticated by scientists at the National Botanical Gardens in 
Bloemfontein, Free State, South Africa. Voucher specimen number MASH 200 was 
allocated to the plant. 
 3.7.2 Consumables and instruments utilized in the study  
The apparatus used in the study were serviced according to schedule and properly 
maintained. Instruments for biochemical and haematological analysis were calibrated 
accordingly, and the quality control results were within reference ranges. Table 3.1 
indicates the instruments used during the procedures, the supplier and test(s) 
performed.  
 
 
  
© Central University of Technology, Free State
27 
 
Table 3.1 Instruments / equipment used during the procedures. 
Instrument Supplier Tests performed  
   
Dimension®Xpand®Plus Siemens Aspartate aminotransferase 
(AST) 
  Alanine aminotransferase 
(ALT) 
  Alkaline Phosphatase (ALP) 
  Blood Urea Nitrogen (BUN) 
  Creatinine 
  Cholesterol 
   
ABX Pentra 60 The Scientific Group Full Blood Count (FBC) 
   
H2500 Microprocessor Energy Beam Sciences Inc. Tissue processing 
Shandon Histocentre Optolabor (Pty)(Ltd) Tissue embedding 
Leica Waterbath Leica Biosystems Nussloch 
GmbH 
Tissue floating 
Leica Microtome Leica Biosystems Nussloch 
GmbH 
Tissue slicing 
Oven Labcon Dewaxing 
Zeiss Microscope. Zeiss South Africa Histological investigations  
Macsalab Mill Eriez South Africa Pulverizing of roots material 
VIRTIS 5L Freeze Dryer SP Scientific Lyophilisation  
 
Tables 3.2, 3.3, 3.4 display reagents consumed for haematological, biochemical and 
histological investigations respectively. 
 
Table 3.2 Consumables for haematologic analytes. 
Controls/ reagents  Catalogue No.  Supplier 
ABX control L  2062207  The Scientific Group 
ABX control H  2062208  The Scientific Group 
ABX control N  2062203  The Scientific Group 
ABX Diluent  0901020  The Scientific Group 
ABX Eosinofix  0206010  The Scientific Group 
ABX Basolyse  0906003  The Scientific Group 
ABX Alphalyse  0906013  The Scientific Group 
ABX Cleaner  0903010  The Scientific Group 
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Table 3.3 Consumables for biochemical analytes. 
Reagent/consumable Catalogue No. 
(Reagent) 
Catalogue No. 
(Calibrator) 
Supplier 
ALP DF15A DC19 Siemens 
ALT DF143 DC143 Siemens 
AST DF41A DC19 Siemens 
BUN DF21 DC18D Siemens 
CHOL DF27 DC16 Siemens 
CREATININE DF33A DC18D Siemens 
ABS (CONTROL) DF79 - Siemens 
 
 
Table 3.4 Consumables for histological investigations. 
Reagent/consumable Catalogue No. Supplier 
Ethanol 1044735 UniVar 
Isopropanol 5075040LC Saarchem 
Paraffin wax CLSC4902000EM Lasec 
Xylene 7220220LC Saarchem 
Haematoxylin 3403747 BDH 
Eosin 34197 BDH 
Entellan 1.07961.0500 Merck  
Coverslips C9802 Sigma Aldrich 
Slides S8902 Sigma Aldrich  3.8 Methods 
 3.8.1 Plant Extraction Methods 
 
The plant material (A. laricinus) was authenticated by scientists at the National 
Botanical Gardens in Bloemfontein, South Africa. The collected root materials were 
dried at room temperature, pulverised by a Macsalab Mill (Model 200, LAB) and 
weighed. The powder was then stored at room temperature until analysis. Plant 
material (10 grams of the dried roots) was soaked in a volume of 500 ml of ethanol, 
dichloromethane or purified water for 72 hours under shaking conditions (120 rpms). 
The supernatant was filtered passively through a Whatman® filter paper, 11 cm in 
diameter. The solvent (ethanol) was removed completely under vacuum, by using a 
speed evaporator (Univapo 100H) at 50°C.The aqueous sample was lyophilised for 
72 hours in the VIRTIS 5 L freeze dryer (VIRTIS New York, USA) to obtain a dried 
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powdered plant extract. The dried samples were then reconstituted in either water or 
ethanol. 
 3.8.2 Plant extracts administration method  
 
Seventy eight Sprague- Dawley rats were divided into three groups; 24 for the water 
extract, 30 for ethanol and 24 for dichloromethane extracts. 
 
Group 1: Water extract  
 
It consisted of 24 rats which were further subgrouped into 4 groups of 6 rats per 
subgroup. Although we had six rats per group, they were further grouped into two rats 
per cage (see Figure 3.1) as per rules and regulations governing the use of laboratory 
animals. Water extracts were diluted to prepare 2%, 10% and 20% concentrations. 
The different concentrations were administered to three of the four groups ad libitum. 
The last group served as controls, where tap water was administered instead of the 
extract. The extracts were administered over a period of eight weeks, using a 200ml 
feeding bottle per cage. Bottles were cleaned and replaced with a fresh extract after 
every two days. 
 
Figure 3.1 Setup for different water extracts and control group (each column 
represents a group and each cage contains two rats). 
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Group 2: Ethanol extract  
 
It consisted of 30 rats which were further subgrouped into 5 groups of 6 rats per 
subgroup. Although we had six rats per group, they were further grouped into two rats 
per cage as per rules and regulations governing the use of laboratory animals. Ethanol 
extracts were administered once per day for two weeks. The extracts were 
administered through gavage by varying the volumes, resulting in the amounts as 
indicated in the table below: 
 
Table 3.5 Animal groups and doses of ethanol extracts per day 
 Extract dose(mg/kg/day) 50 100 200 400 Controls 
Number of rats per group 6 6 6 6 6 
 
Although the controls had water ad libitum, water was administered by gavage every 
time the exposed groups were administered with the extracts. 
 
Group 3: Dichloromethane extract 
 
According to the proposal, different amounts as per table below were supposed to be 
administered intramuscularly. Due to the nature of pain and ulcerations resulting from 
repetitive intramuscular injections on the tails of rats over a two-week period, scientists 
at the Animal Research Unit recommended a switch over to gavage feeding. The 
process was immediately stopped due to the death of  two rats within a few minutes 
after administration of the extract through gavage. Administration of dichloromethane 
was discontinued and this group was completely excluded from the research project. 
 
Table 3.6 Animal groups and doses of dichloromethane extracts per day 
Amount of extract per day 50mg/kg 100mg/kg 200mg/kg 400mg/kg 
Number of rats per group 6 6 6 6 
 3.8.3 Sample collection 
 
The rats were placed in a desiccator with Halothane (Safeline Pharmaceuticals) 
soaked in cotton wool for anaesthetic purposes until they were completely 
unconscious. Blood samples were collected in EDTA anticoagulated tubes 
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(haematological analysis) and non-anticoagulated tubes (clotted blood for biochemical 
analysis) through insertion of the needle into the heart. The rats were administered 
with further halothane for euthanization. The blood collection process was done by 
scientist employed by the Animal Research Unit at the University of the Free State. 
Liver, spleen and kidneys were excised (by the researcher) and immediately 
preserved with 10% Neutral Buffered Formalin for histological investigations. 
 3.8.4 Laboratory investigations   
Substances ingested by animals including food, medication and fluids (extracts in our 
case) are absorbed in the gastrointestinal tract after digestion. Absorbed substances 
are transported to the liver via the portal vein for detoxification and further processing 
and distribution throughout the body tissues and organs via the vascular system 
(blood). Blood passes through the kidneys where it is filtered in the nephrons, and 
where unwanted and waste products are excreted in urine. 
 
The presence of toxic substances in ingested material may cause damage to tissues 
and organs such as the liver, kidneys and blood cells in circulation. The extent of the 
damage may also be associated with the period of exposure and the amount/ 
concentration of substances in circulation.  
 
Selected biochemical tests include enzymes such as aspartate aminotransferase 
(AST); alanine aminotransferase (ALT); alkaline phosphatase (ALP) which assesses 
the extent of the damage to hepatic tissues. Blood urea nitrogen and creatinine are 
specifically selected for the assessment of kidney function, and would therefore reflect 
damage to the nephrons and other tissues of the kidney. Blood urea nitrogen (BUN) 
and creatinine clearance are well established biomarkers of renal function that can be 
measured cheaply and easily using an enzyme/oxidation reaction assay and high 
performance liquid chromatography (HPLC), respectively (Mouton & Holder, 2006). 
Lastly, cholesterol is necessary for the assessment of damage to the heart and 
vascular system. 
 
Haematological tests would reflect damage to the blood cells (red blood cells, white 
blood cells and platelets) because these cells would be exposed to toxic substances 
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during transportation in the vascular system. Apart from the above-mentioned analytes, 
histological investigation of the organs/ tissues excised will assess the damage caused 
by such substances, as well as the extent of the damage. 
 
Blood samples for biochemical analysis were allowed to clot, followed by centrifugation 
at 3000rpm for 10 minutes. Serum was collected in 2ml tubes and analysed within five 
hours, and some aliquots stored in a refrigerator set at 4°C.The samples were kept for 
one week in order to allow repeat analysis in case of unreliable, doubtful or inaccurate 
results. 
 
Haematology samples were analyzed within five hours using the ABX Pentra 60. All 
three levels of quality control samples were run in conjunction with the rats’ blood for 
every batch of samples. 
 3.8.4.1 Biochemical parameters 
 
Quantitative analysis of Aspartate aminotransferase (AST); Alanine aminotransferase 
(ALT); Alkaline phosphatase (ALP); Cholesterol (CHOL); blood urea nitrogen (BUN) 
and Creatinine were performed using Dimension XpandPlusTM auto analyzer (supplied 
by Siemens). 
 3.8.4.1.1 Principle for the determination of Aspartate aminotransferase 
 
Aspartate aminotransferase (AST) catalyzes the transamination from L-aspartate to 
α-ketogluterate, forming L-glutamate and oxaloacetate. The oxaloacetate formed is 
reduced to malate by malate dehydrogenase (MDH), with simultaneous oxidation of 
reduced nicotinamide adenine dinucleotide (NADH). The change in absorbance with 
time due to the conversion of NADH to NAD is directly proportional to the AST activity 
and is measured using a bichromatic (340nm, 700nm) rate technique (Bergmeyer et 
al., 1978). 
 3.8.4.1.2 Principle for the determination of Alanine aminotransferase 
 
Alanine aminotransferase catalyzes the transamination of L-alanine to α-ketogluterate, 
forming L-glutamate and pyruvate. The pyruvate formed is reduced to lactate by 
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lactate dehydrogenase (LDH) with simultaneous oxidation of reduced NADH. The 
change in absorbance is directly proportional to the alanine aminotransferase activity 
and is measured using a bichromatic (340nm, 700nm) rate technique (Bergmeyer et 
al., 1978). 
 3.8.4.1.3 Principle for the determination of Alkaline phosphatase 
 
Alkaline phosphatase catalyzes the transphosphorylation of p-nitrophenylphosphate 
(p-NPP) in the presence of the transphosphorylating buffer, 2-amino-2-methyl-1-
propanol (AMP). The reaction is enhanced through the use of magnesium and zinc 
ions. The change in absorbance at 405 nm due to the formation of p-nitrophenol (p-
NP) is directly proportional to the ALP activity, since the reactants are present in non-
rate-limiting quantities and is measured using a bichromatic (405 nm, 510 nm) rate 
technique (Bowers & McComb,1966). 
 3.8.4.1.4 Principle for the determination of Cholesterol 
 
Cholesterol esterase (CE) catalyzes the hydrolysis of cholesterol esters to produce 
free cholesterol, which, along with pre-existing free cholesterol, is oxidized in a 
reaction catalyzed by cholesterol oxidase (CO) to form cholest-4-ene-3-one and 
hydrogen peroxide. In the presence of horseradish peroxidase (HPO), the hydrogen 
peroxide thus formed is used to oxidize N,Ndiethylaniline-HCl/ 4-aminoantipyrine 
(DEA-HCl/AAP) to produce a chromophore that absorbs at 540 nm. The absorbance 
due to oxidized DEA-HCl/AAP is directly proportional to the total cholesterol 
concentration, and is measured using a polychromatic (452, 540, 700 nm) endpoint 
technique (Rautela & Liedtke, 1978). 
 3.8.4.1.5 Principle for the determination of BUN (Blood Urea Nitrogen) 
 
Urease specifically hydrolyzes urea to form ammonia and carbon dioxide. The 
ammonia is used by the enzyme glutamate dehydrogenase (GLDH) to reductively 
aminate α-ketoglutarate, with simultaneous oxidation of reduced NADH. The change 
in absorbance at 340 nm due to the disappearance of NADH is directly proportional to 
the BUN concentration in the sample and is measured using a bichromatic (340 nm, 
383 nm) rate technique (Burtis & Ashwood, 2001). 
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 3.8.4.1.6 Principle for the determination of Creatinine 
 
In the presence of a strong base such as NaOH, picrate reacts with creatinine to form 
a red chromophore. The rate of increasing absorbance at 510 nm, due to the formation 
of this chromophore is directly proportional to the creatinine concentration in the 
sample and is measured using a bichromatic (510, 600 nm) rate technique. Bilirubin 
is oxidized by potassium ferricyanide to prevent interference (Knapp & Mayne, 1987). 
 3.8.4.2 Haematological parameters 
 
An ABX Pentra 60 analyzer was used to determine the haematological parameters. 
Haematological parameters determined in this study included Red Blood Cell count 
(RBC), Haemoglobin (Hb), Haematocrit (Hct), Mean Cell Volume (MCV), Mean Cell 
Haemoglobin (MCH), Mean Corpuscular Haemoglobin Concentration (MCHC), White 
Blood Cell count (WBC), differential count and platelet count (Plt). 
 
The analyzer uses the multi distribution sampling system (MDSS) where one cycle is 
distributed into 3 blood samples for RBC/Plt, BASO/WBC and LMNE matrix which are 
channelled to the three respective chambers with reagents. The different full blood 
count parameters where analysed using current impedance changes; 
spectrophotometry; double hydrodynamic sleeving coupled with cytochemistry; and 
measuring of transmitted light; to measure the different parameters of the full blood 
count (Nakamine , 2004:2-13). 
 3.8.4.2.1 Principle for the detection of RBC and Platelets 
 
The analyzer uses the measurement of impedance variation generated by the 
passage of cells through a calibrated micro aperture. The specimen is diluted in 
electrolytic diluents (good conductor of current) and pulled through the calibrated 
micro-aperture. Two electrodes are placed on either side of the aperture. Electric 
current passes through the electrodes continuously. When the cell passes through the 
aperture, electric resistance between the two electrodes increases proportionately 
with the cell volume. 
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 3.8.4.2.2 Principle for the detection of Haemoglobin 
 
Red blood cells are lysed and the haemoglobin released combines with potassium 
cyanide to form a chromogenous cyanmethaemoglobin compound. The compound is 
measured through the optical part of the first dilution chamber using a 
spectrophotometric technique at a wavelength of 550nm. The absorbance obtained is 
multiplied by the coefficient of calibration in order to get the actual concentration in 
g/100ml. 
 3.8.4.2.3 Principle for the detection of Haematocrit 
 
The height of the impulse generated by the passage of a cell through the micro-
aperture is directly proportional to the volume of the analyzed RBC. This data is utilised 
for calculation of MCV, which is used for calculation of haematocrit. The haematocrit 
is measured as a function of numeric integration of the MCV. 
 3.8.4.2.4 Calculations for MCV, MCH, and MCHC 
 
• MCV (Mean Cell Volume) is calculated directly from the RBC histogram. 
• MCH (Mean Cell Haemoglobin) is calculated from the Hb value and the RBC 
number. 
The mean haemoglobin weight in each RBC is given by the formula: 
MCH (pg) = Hb/RBC X10 
• MCHC (Mean Corpuscular Haemoglobin Contained) is calculated according to 
the Hb and Hct values. Mean Hb concentration in the total volume of RBC is 
given by the formula: 
MCHC= Hb/Hct X100 
 3.8.4.2.5 WBC and differential count 
 
General principles 
The WBC count is carried twice by two different sensors: 
• In the BASO count chamber at the same time as BASO count. 
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• In the optical chamber during the acquisition of the LMNE matrix. 
The reference count is the one obtained in the WBC and BASO count chamber. 
 3.8.4.2.6 BASO/WBC count 
 
• Detection principle is the same as RBC. 
Differentiation between BASOs and other leukocytes is obtained by means of 
BASOLYSE II specific lysing action. 
 
• All the WBCs are counted between the electrical threshold <0> and threshold 
<BA3>. 
The basophils are located from threshold <BA2> to threshold <BA3>. 
Actual results are obtained as follows: 
WBC: Number of cells per volume x coefficient of calibration. 
BASO: Number of cells per volume x coefficient of calibration in percentage regarding 
the total number of leukocytes (BASO + WBC nuclei). 
 
LMNE matrix 
The WBC and Differential count are based on 3 essential principles: 
• The double hydrodynamic sleeving (DHSS). 
• The volume measurement impedance changes. 
• The measurement of transmitted light with 0° angle, which permits a response 
according to the internal structure of each element and its absorbance by 
means of incident light diffusion. 
25µl of whole blood is delivered to the LMNE chamber in a flow of EOSINOFIX. This 
reagent lyses the RBC, stabilizes the WBC in their native forms and stains the 
eosinophil nuclei with specific colouration. The solution is then stabilized and 
transferred to the measuring chamber. Each cell is then measured both in absorbance 
(cytochemistry) and resistivity (volume). 
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Results 
A matrix is drawn up with the volumes on the X-axis and optical transmission on the 
Y-axis from the above measurements. The study of the matrix image permits the clear 
differentiation of 4 out of the 5 leukocyte population. 
 3.8.4.3 Histological Investigations 
 
The liver, spleen and kidneys are prime targets for histological investigations because 
they are involved in the degradation and excretion of a myriad of chemical compounds. 
Renal damage has been associated with the use of the medicinal plants in the 
treatment of different disorders, including diabetes mellitus (Mapanga & Musabayane, 
2010). 
 3.8.4.3.1 Preservation/fixation 
 
Excised liver, kidney and spleen tissues were immediately placed in 10% Formalin for 
fixation. They were stored in separate specimen bottles at room temperature until 
processed.  
 3.8.4.3.2 Processing 
 
The samples were sliced into smaller tissues, stored in labelled histology cassettes 
before processing. They were processed with a microwave technique (Leong, 1991), 
using a H2500 microwave processor supplied by Energy Beam Sciences, Inc. 
 
Tissue samples were immersed in a 100% ethanol container and placed in the 
microwave at 67°C for 16 minutes. Ethanol was discarded and the procedure repeated 
for a further 16 minutes. This was followed by immersion of the samples in 100% 
isopropanol and incubation at 60°C for 15 minutes. The step was repeated with fresh 
100% isopropanol for a further 15 minutes. In all steps mentioned above, the container 
was loosely covered and agitated at all times. In the next two steps of the procedure, 
tissue samples were immersed in paraffin wax for 15 minutes each and the 
temperature was set at 65°C and 80°C respectively. 
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3.8.4.3.3 Embedding and tissue slicing  
 
The samples were embedded in paraffin wax using the Shandon HistoCentre, 
distributed by Optolabor (PTY) (LTD) in South Africa, according to the following 
procedure: 
The cassettes containing processed tissues were removed from the wax container 
in the last processing step and placed on the heat section of the embedding 
instrument. The metal mould was heated slightly for each tissue, filled with molten 
paraffin wax and the tissue positioned in the molten wax using forceps. The 
labelled plastic mould of the cassette was placed onto the metal mould, filled 
completely with molten paraffin wax and placed on the cold plate for the wax to 
harden. 
 
Samples were cut into thin slices (5µm) using LeicaTM microtome, floated in a water 
bath and picked with slides and labelled according to the plastic mould. 
 
The wax was allowed to melt in an oven set at 57°C for 30 minutes and the slides were 
stained. 
 3.8.4.3.4 Staining 
 
The slides were stained with Hematoxylin and Eosin (H&E) procedure as depicted in 
Table 3.7 below. 
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Table 3.7: Hematoxylin and Eosin stain 
Step Process  Solution  Timing 
1 De-wax Xylene  5 minutes 
2 De-wax Xylene 3 minutes 
3 Hydrate  100% ethanol 1 minutes 
4 Hydrate 95% ethanol 30 seconds 
5 Hydrate 70% ethanol 30 seconds 
6 Hydrate water  30 seconds 
7 Nuclear stain Mayer’s Haematoxilyn 5 minutes 
8 Rinse Water 30 seconds 
9 Differentiate 1% acid alcohol 30 seconds 
10 Blueing Scott’s tap water 1 minute 
11 Cytoplasmic stain Eosin 5 minutes 
12 Dehydrate  70% ethanol 30 seconds 
13 Dehydrate 90% ethanol 30 seconds 
14 Dehydrate 100% ethanol 1 minute 
15 Clearing  Xylene  1 minute 
16 Clearing Xylene  1 minute 
Slides were mounted with a coverslip using Entellan. 
 
Cases and controls were diagnosed microscopically at 40X magnification by a 
pathologist at the Universitas Academic Complex, Bloemfontein. A total of 486 slides 
were microscopically evaluated because three tissues were sliced from different 
anatomical regions of the organs The pathologist  specifically undertook macrosopic 
and microscopic investigations for variations on the tissues excised.  
 
Macroscopically, he investigated the presence of abnormal architecture of the tissue 
parenchyma on all specimens. Microscopically, he investigated any signs of dysplasia 
in terms of cellular changes, viz, nuclear pleomorphism, high nuclei-cytoplasm ratio, 
nuclear hyperchromasia, necrosis and abnormalities observed during mitosis. Any 
signs of inflammation were also investigated microscopically.  
 3.9 Statistical analysis 
Data was captured in Microsoft Excel® by the researcher. Any further analysis was 
done by a statistician using SAS Version 9.2. Descriptive statistics, namely 
frequencies and percentages, were calculated for categorical and medians, and 
percentiles were calculated for numerical data. The normality of the numerical 
variables were tested using Shapiro-Wilk’s test, and if a variable was skewed (p < 
0.05) the median and inter-quartile range (IQR) was reported. Analytical statistics, 
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namely the Kruskal-Wallis test, was used to compare median values between the 
control and experimental groups, as well as to compare the median values between 
the different extract concentrations. A significance level of 0.05 was used. 
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CHAPTER 4 
 
RESULTS  4.1 Introduction 
 
The aim of the study was to evaluate the possible toxic effects of Asparagus laricinus 
extracts using Sprague Dawley rats as the animal model..The rats were exposed to 
different plant extracts in ethanol, dichloromethane and water at different 
concentrations and doses. The dichloromethane extract procedure was discontinued 
due to adverse events as mentioned in the methodology section. 
 
In this chapter, we focused closely at statistical analysis of different laboratory results 
with reference to haematological and biochemical parameters in blood samples, as 
well as the histological assessment of tissues excised from the kidney, liver and spleen. 
Haematological and biochemical variables were compared, firstly, between exposed 
and unexposed groups, and secondly, also within groups in both ethanol and aqueous 
extracts. Macroscopic and microscopic assessment of tissues excised were done by 
investigations of morphologic and functional changes by comparing organs as well as 
histological slides preparation between exposed and unexposed animals. 
 4.2 Comparison of results obtained for the control group and the experimental population 
 
The results of the combined control and experimental groups are presented in this 
section, starting with mass, followed by haematological, clinical chemistry parameters 
and wrapping it up with histological investigations.  Statistical analysis for comparing 
controls and treatment groups for both aqueous and ethanolic groups at increasing 
dosages are also presented. In addition, the difference within the different extract 
concentrations for aqueous and ethanol groups is illustrated in the section. 
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4.2.1 Mass 
 
The median weight of all controls (n=12) and the experimental group combined (n=42) 
were statistically compared using Kruskal-Wallis test. No significant differences 
(p>0.05) between the median weights of unexposed and exposed rats at the start and 
termination of the experiment was observed, as illustrated by Table 4.1. 
 
Table 4.1 Median change in weight of the controls (unexposed) and experimental  
     (exposed) rats. 
  Median IQR Min – Max  p-value 
Start 
mass (g) 
Control 180.0 178.0-188.5 158.0-201.0 0.252 
Experimental 188.0 179.0-193.0 164.0-204.0 
End mass 
(g) 
Control 216.5 211.5- 238.0 209.0-271.0  0.102 
Experimental 225.0 220.0-244.0 201.0-265 
Change 
in Mass 
Control 41.5 33.0-54.5 19.0-70.0 0.700 
Experimental 44.0 33.0-56.0 7.0-74.0 
IQR (Interquartile Range), Min (Minimum), Max (Maximum) g (Grams) 
 4.2.2 Haematological parameters  
Comparison studies for full blood count parameters between controls (n=12) and 
combined experimental group (n=42) were performed. There were no significant 
differences (p>0.05) between combined controls and experimental animals regarding 
haematological parameters of the combined ethanol and aqueous extracts at different 
levels/doses (Table 4.2 & 4.3). 
 
Table 4.2 Comparison of RBC parameters between combined controls and 
experimental groups. 
IQR (Interquartile Range), RBC (Red Blood Cells), HB (Haemoglobin g/dl), HCT 
(Haemoglobin Content %), MCV (Mean Cell Volume) fl (Femtoliters), MCH (Mean Cell 
Haemoglobin), pg (Picograms), MCHC (Mean Cell Haemoglobin Content g/dl) 
 
 
 
 
  RBC 
( x109 /l) 
HB (g/dl) HCT (%) MCV (fl) MCH 
(pg) 
MCHC 
(g/dl) 
Median Control 7.67 15.10 42.20 56.00 19.80 35.40 
Exposed 7.87 15.5 43.60 56.00 19.80 35.65 
IQR Control 7.5-8.1 14.8-15.3 41.4-43.6 54.0-56.0 19.0-19.9 35.3-35.9 
Exposed 7.4-8.1 14.9-16.0 41.5-45.0 55.0-56.0 19.6-20.1 35.4-35.8 
p-value 0.820 0.183 0.320 0.537 0.655 0.516 
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Table 4.3 Comparison of white cell parameters and platelet between combined controls  
      and experimental groups. 
WBC (White Blood Cells x109 /l), LYM (Lymphocytes x109 /l), MON (Monocytes x109 /l), 
NEU (Neutrophils x109 /l), EOS (Eosinophils x109 /l), BAS (Basophils x109 /l), PLT (Platelets 
x109 /l)  
 4.2.3 Biochemical parameters  
Liver enzymes, cholesterol, urea and creatinine results for the combined groups of 
ethanol and aqueous extract controls (n=12); in comparison with combined different 
treatment groups (n=42) were statistically analysed using a Kruskal-Wallis test . Again, 
no significant statistical differences (p>0.05) across the different extracts and levels of 
concentrations were observed (Table 4.4). 
 
Table 4.4 Comparison of biochemical parameters between combined controls and  
      experimental groups. 
(P<0.05) statistically significant; CHOL (Cholesterol). BUN (Blood Urea Nitrogen), CREAT 
(Creatinine), ALP (Alkaline Phosphatase), AST (Aspartate Aminotransferase), ALT (Alanine 
Aminotransferase).  
  WBC  LYM MON NEU EOS BAS PLT 
Media
n 
Control 3.70 2.83 0.32 0.48 0.03 0.03 734.0 
Exposed 4.25 3.45 0.36 0.54 0.02 0.03 795.0 
IQR Control 2.6-5.1 1.91 -
3.80 
0.16 -
0.45 
0.37 –
0.57 
0.02 -
0.05 
0.02 -
0.04 
669.0-
753.0 
Exposed 3.2-5.8 2.60 -
4.47 
0.17 -
0.43 
0.35 -
0.84 
0.01 -
0.09 
0.02 -
0.03 
690.0-
826.0 
p-value 0.436 0.443 0.848 0.429 0.737 0.3500 0.057 
  CHOL BUN CREA ALP AST ALT 
Median Control 2.00 6.25 47.00 107.5 125.00 58.50 
Exposed 2.00 6.00 29.00 131.0 123.50 53.00 
IQR Control 2.00-2.00 5.85-6.85 14.50-
74.50 
92.00-
141.50 
101.50-
185.50 
51.00-
86.00 
Exposed 2.00-2.00 5.40-6.50 12.00-
71.00 
91.00-
151.00 
102.00-
164.00 
45.00-
66.00 
p-value 0.061 0.215 0.876 0.365 0.9254 0.219 
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4.3 Comparative study of the control group versus the various ethanol extract group 
 
In this section, the statistical analysis for comparing controls and treatment groups of 
ethanoic groups, at increasing dosages, are presented. This was done to determine 
the effects of lower and higher ethanol extract concentration on the parameters. 
 4.3.1 Mass 
 
Table 4.5 below represents the statistical analysis of the comparison of the weight of 
rats (in grams) for the control (n=6) and treatment groups, at increasing dosages of 
ethanoic extracts ranging from 50mg/kg/day to 400mg/kg/day. Significant differences 
were observed for the initial mass of rats exposed to 200mg/kg/day (p=0.0100), and 
also for the termination mass of rats exposed to 400mg/kg/day (p=0.0303). There was 
no difference in the change of mass for the rest of the dosages administered. 
 
Table 4.5 Median weight of controls (unexposed) and experimental (exposed)  
      rats at different levels of ethanol extract 
 Control Amount of ethanol extract (mg/kg/day) 
50 100 200 400 
Start 
mass 
Median 180.0 183.0 186.0 193.0 187 
IQR 179.0-183.0 173.0-191.0 184.0-189.0 190.0-197.0 183.0 -
189.0 
p-value 0.8717 0.1978 0.0100* 0.2265 
End mass Median 214.0 219 222.0 222.5 230.50 
IQR 211.0-217.0 217.0-220.0 220.0-224.0 217.0-225.0 223.0-244.0 
p-value 0.2281 0.0782 0.921 0.0303* 
Change 
in mass 
Median 33.0 36.0 39.5 31.5 47.5 
IQR 30.0-37.0 29.0-44.0 33.0-43.0 24.0-33.0 34.0-55.0 
p-value 0.873 0.333 0.420 0.078 
*(P<0.05) statistically significant. 
 
Figure 4.1 below illustrates the graphical presentation of the differences between the 
initial and termination median masses at increasing ethanol extract doses. These 
clearly illustrates that the median change in weight over the two weeks experimental 
period is slightly below 50mg. It is also observed that rats exposed to 200mg/kg/day 
dose had the least weight change, while those exposed to a 400mg/kg/day dose had 
the most. These changes were not statistically significant. 
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Figure 4.1 Graphical representation of the median change in mass for the rats on 
ethanol extracts.  4.3.2 Haematological parameters 
 
Full blood counts were determined for the rats treated with ethanol extracts at different 
doses ranging from 50mg/kg/day to 400mg/kg/day. A Kruskal-Wallis test for 
comparing median results was performed and the results showed no significant 
difference between the control (n=6) and treatment groups (n=6) across most levels 
of ethanoic extracts.  
 
Table 4.6 Comparison of WBC and PLT between controls and rats exposed to    
                    ethanol extracts across all doses. 
*(P<0.05) statistically significant; WBC (White blood cells x109 /l), LYM (Lymphocytes x109 
/l), MON (Monocytes x109 /l), NEU (Neutrophils x109 /l), EOS (Eosinophils x109 /l), BAS 
(Basophils x109 /l), PLT (Platelets x109 /l) 
 
0
50
100
150
200
250
Control Ethanol 50 Ethanol 100 Ethanol 200 Ethanol 400
Start(g)
End(g)
Change in Weight
  WBC LYM MON NEU EOS BAS PLT 
Median Control 3.80 3.01 0.40 0.46 0.03 0.04 730.00 
Exposed 50mg/kg  4.20 3.43 0.36 0.53 0.02 0.03 850.00 
p-value 0.233 0.144 0.465 0.584 0.465 0.097 0.011* 
 Exposed 100mg/kg 3.60 2.78 0.33 0.42 0.01 0.03 762.00 
p-value 0.410 0.855 0.584 0.170 0.462 0.139 0.201 
 Exposed 200mg/kg 4.95 4.03 0.33 0.58 0.02 0.03 783.00 
p-value 0.394 0.201 0.394 1.00 1.00 0.159 0.394 
 Exposed 400mg/kg 5.75 3.93 0.40 0.60 0.02 0.03 839.00 
p-value 0.575 0.748 0.200 1.00 0.872 0.059 0.0547 
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Table 4.6 illustrates significant differences (p=0.0106) in the median results of platelets 
at the dosage of 50mg/kg/day. It must be noted that the percentage change from the 
control median (730 x 109/L) to 50mg/kg (850 x 109/L), was 16%, while the human 
refence range is 150 – 410 x109/L (Bates & Lewis, 2011). The human range spans 
over a range of 63%. Furthermore, it must be noted that the 400mg/kg group’s platelet 
median was 839 x 109/L, which showed a 13%  change with no statistical significant 
difference. The remaining parameters in both Tables 4.6 and 4.7 could not 
demonstrate any significant differences statistically (p>0.05). 
 
Table 4.7 Comparison of red blood cells parameters between unexposed and  
      exposed rats for ethanol extracts across all doses. 
IQR (Interquartile range), RBC (Red blood cells x109 /l), HB (Haemoglobin g/dl), HCT 
(Haemoglobin content %), MCV (Mean Cell Volume in microtoliters), MCH (Mean Cell 
Haemoglobin Picograms), MCHC (Mean Cell Haemoglobin Content g/dl) 
 
It is of utmost importance to emphasize that the results for full blood count parameters 
are expressed in varying units, and therefore fewer figures for comparison of their 
medians would not be practical at this stage.  
 
  
  RBC HB HCT MCV MCH MCHC 
Median Control 7.50 15.05 42.10 56.00 19.85 35.70 
Exposed 50mg/kg 7.95 15.70 44.10 56.00 19.80 35.80 
p-value 0.273 0.1190 0.143 0.827 0.700 0.855 
Median Control 7.50 15.05 42.10 56.00 19.85 35.70 
Exposed100mg/kg 7.06 14.40 40.10 56.00 20.10 35.80 
p-value 0.273 0.583 0.464 0.392 0.573 0.855 
Median Control 7.50 15.05 42.10 56.00 19.85 35.70 
Exposed 200mg/kg 7.57 15.15 42.40 56.00 20.10 35.80 
p-value 0.831 0.915 1.00 0.221 0.051 0.669 
Median Control 7.50 15.05 42.10 56.00 19.85 35.70 
Exposed 400mg/kg 7.59 14.95 41.45 55.00 19.80 35.60 
p-value 0.749 0.810 0.748 0.212 0.315 0.809 
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4.3.3 Biochemical parameters 
 
Median results for biochemical tests were compared between the controls (n=6) and 
experimental group (n=6) using a Kruskal-Wallis test.There was no statistical 
difference between the controls and increasing doses of ethanol extracts in all 
biochemical results, as illustrated by Table 4.8. 
 
Table 4.8 Comparison of biochemical parameters between controls and rats 
       exposed to ethanol across all concentrations. 
 
This is further illustrated in figures 4.2, 4.3 and 4.4, which summarizes median results 
for cholesterol and blood urea nitrogen; creatinine and enzymes respectively. These 
constituents were grouped together according to the units in which the results are 
expressed. Table 4.8 illustrates the p-values for biochemical parameters. 
 
 
Figure 4.2 Median results of cholesterol and blood urea nitrogen at increasing 
doses of ethanol extracts. 
0
1
2
3
4
5
6
7
8
CHOL BUN
Cholesterol & BUN (mmol/L): Ethanol 
extract 
Control Ethanol 50 Ethanol 100 Ethanol 200 Ethanol 400
  CHOL BUN CREA ALP AST ALT 
Median Control 2.00 6.55 14.50 141.50 149.00 69.50 
Exposed 50mg/kg 2.00 6.15 8.50 167.00 165.50 72.50 
p-value 1.000 0.688 0.514 0.0542 0.936 0.873 
 Exposed 100mg/kg 2.00 6.90 24.00 146.50 119.50 47.50 
p-value 1.00 0.749 0.199 0.630 0.229 0.078 
 Exposed 200mg/kg 2.00 6.25 14.00 132.00 164.00 65.00 
p-value 1.000 0.422 0.867 0.7479 0.7483 0.747 
 Exposed 400mg/kg 2.00 6.10 23.00 145.50 121.50 54.00 
p-value 1.000 0.127 0.295 0.261 0.229 0.192 
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Figure 4.3 A comparative study of the median creatinine results at increasing doses 
      of ethanol extracts. 
 
 
Figure 4.4 A comparative study of median liver enzymes results at increasing doses 
of ethanol extracts. 
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4.4 Comparative study of the control group versus various aqueous extracts group 
 4.4.1 Mass 
 
The median change in mass for both treated (experimental) and untreated (control) 
groups over the experimental period (8 weeks), were recorded. Results for controls 
and experimental groups were compared using a Kruskal-Wallis test. There was no 
significant difference (p>0.05) in the median mass between the controls (n=6) and all 
experimental groups (n=18), as illustrated in Table 4.4. Furthermore, the change in 
median weights throughout the entire experimental period was approximately 50g, as 
illustrated by Figure 4.5 below. 
 
Table 4.9 Median weight of controls (unexposed) and experimental (exposed)  
      rats at different levels of aqueous extracts. 
 Control Concentration of the aqueous extract 
2% 10% 20% 
Start mass Median 181.0 188.0 189.0 181.5 
IQR 176.0-197.0 182.0-188.0 168.0-192.0 173.0-197.0 
p-value 0.5189 0.8728 0.9358 
End mass Median 235.5 246.5 236 236.0 
IQR 215.0-251.0 245.0-252.0 220-242.0 220.0-251.0 
p-value 0.5218 1.000 0.8099 
Change in 
mass 
Median 54.5 60.0 49.5 51.0 
IQR 46.0-66.0 59.0-63.0 48.0-56.0 44.0-54.0 
p-value 0.336 0.631 0.748 
 
 
0
50
100
150
200
250
300
Control 2% Aqueous 10% Aqueous 20% Aqueous
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Change in Weight
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Figure 4.5 Graphical representation of the median change in mass of the rats 
       treated with aqueous extracts over a period of eight weeks. 
The change in weight was similar in all groups, with 2% aqueous extract having a 
slightly higher mass, which was not significant. 
 4.4.2 Haematological parameters 
 
Tables 4.10 and 4.11, that compare the controls (n=6) and experimental groups (n=6) 
at different concentrations of aqueous extracts, specifically with regard to full blood 
count parameters and  p-values, were prepared. There were no significant differences 
in all concentrations ranging from 2% to 10% (p>0.05) in FBC parameters. A significant 
difference was observed for haemoglobin (p=0.0353) in subjects exposed to 20% 
aqueous extracts, as illustrated in Table 4.10. It must be noted that the percentage 
change from control median haemoglobin concentration (15.1g/dl) to 20% aqueous 
(15.85g/dl) was 5%, while the human refence range for males is 13 – 17g/dl (Bates & 
Lewis, 2011). The human range spans over a range of 24%. Furthermore, it must be 
noted that 10% of the aqueous group’s haemoglobin concentration was 15.95g/dl, 
which showed a 6% percentage change with no statistical significant difference. 
 
 
 
 
Table 4.10 Comparison of RBC parameters between controls and exposed rats  
         across all aqueous extracts. 
 
 
 
 
 
 
 
RBC (Red Blood Cells x109 /l), HB (Haemoglobin g/dl), HCT (Haemoglobin Content %), 
MCV (Mean Cell Volume in Microtoliters), MCH (Mean Cell Haemoglobin picograms), 
MCHC (Mean Cell Haemoglobin Content g/dl), *(P<0.05) statistically significant  
 
Table 4.11 Comparison of WBC and PLT parameters between unexposed and 
        exposed rats across all aqueous extracts. 
  RBC HB HCT MCV MCH MCHC 
Median Control 8.04 15.10 42.60 54.00 19.00 35.30 
Exposed 2% 7.99 15.45 43.75 55.50 19.70 35.55 
p-value 0.784 0.234 0.314 0.453 0.357 0.409 
 Exposed 10% 8.08 15.95 45.20 56.00 19.65 35.55 
p-value 0.715 0.361 0.465 0.344 0.359 0.4059 
 Exposed 20% 7.98 15.85 44.70 55.50 19.60 35.40 
p-value 0.521 0.035* 0.082 0.396 0.356 0.348 
  WBC LYM MON NEU EOS BAS PLT 
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WBC (White Blood Cells x109), LYM (Lymphocytes x109 /l), MON (Monocytes x109 /l), 
NEU (Neutrophils x109 /l), EOS (Eosinophils x109 /l), BAS (Basophils x109 /l), PLT (Platelets 
x109 /l) 
 4.4.3 Biochemical parameters 
 
Several figures were created for the comparison of the median results of controls (n=6), 
and experimental results (n=6) for the increasing doses of aqueous extracts. Table 
4.12 summarizes the medians and p-values across increasing aqueous extracts. No 
significant differences were observed throughout increasing doses of aqueous 
extracts in biochemical parameters, except for the blood urea nitrogen (p=0.0081) for 
animals exposed to 20% aqueous extract. Figures 4.7 to 4.8 illustrates a summary of 
comparisons of median results between the controls (n=6) and experimental groups 
(n=6), at increasing doses of aqueous extracts for biochemical parameters. 
 
 
Table 4.12 Comparison of biochemical parameters between controls and  
         exposed rats across all aqueous extract. 
*(P<0.05)statistically significant ; CHOL (Cholesterol), BUN (Blood Urea Nitrogen), 
CREAT (Creatinine), ALP (Alkaline Phosphatase), AST (Aspartate Amino Transferase), 
ALT (Alanine Aminotransferase). 
 
Median Control 3.40 2.3 0.17 0.52 0.02 0.02 734 
Exposed 2% 3.40 2.63 0.26 0.48 0.01 0.02 721.50 
p-value 0.855 0.855 0.359 1.000 0.645 0.130 0.465 
 Exposed 10% 3.90 2.83 0.29 0.60 0.03 0.02 710.50 
p-value 0.715 0.144 0.464 0.143 0.578 0.082 0.855 
 Exposed 20% 5.25 4.11 0.33 0.66 0.05 0.03 724.00 
p-value 0.201 0.855 0.714 0.583 0.782 0.121 1.000 
  CHOL BUN CREA ALP AST ALT 
Median Control 2.00 6.15 74.5 92.00 101.5 56.5 
Exposed 2% 2.00 5.85 80.00 89.50 100.50 47.50 
p-value 0.3173 0.4217 0.1488 0.7471 0.5745 0.5738 
 Exposed 10% 2.00 5.95 69.00 88.00 136.00 53.50 
p-value 0.3137 0.9356 0.1978 0.8726 0.4233 0.3350 
 Exposed 20% 2.00 5.05 73.00 98.00 111.00 53.00 
p-value 0.3173 0.0081* 0.7483 0.8726 0.5189 0.9361 
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Figure 4.6 A comparative study of median cholesterol and BUN results at 2%, 10%  
        and 20% of water extracts. 
 
 
 
Figure 4.7 A comparative study of median creatinine results at increasing doses of  
        water extracts. 
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Figure 4.8 A comparative study of median liver enzymes results at increasing doses  
                 of water extracts.  
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4.5 Histological investigations 
 
Macroscopic examination of the kidney, liver and spleen tissue could not demonstrate 
any pathological variations between the treatment groups and controls in both 
aqueous and ethanol extracts, as assessed by the pathologist. A histopathological 
study of the rats’ kidney, liver and spleen tissue indicated a normal architecture of 
tissue in both the controls and treatment groups, as illustrated in Figures 4.9 to 4.11, 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Photomicrographs of the longitudinal sections of the renal cortex region 
of control and treated animals. (A) Renal cortex of control (aqueous 
extract) rats showing glomeruli (40×). (B) Treated with 2% aqueous 
extract of Asparagus laricinus.(40×). (C) Renal cortex of a control 
(ethanol extract) rat showing glomeruli (40×). (D) Treated with 
50mg/kg/day ethanol extract (40×). 
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Figure 4.10 Effect of aqueous and ethanol extracts of Asparagus laricinus on the liver 
tissue of Sprague Dawley rats. (E) Control tissue for aqueous extracts 
(40×). (F) Treated with 10% aqueous extract. (40×). (G) Control rats for 
ethanol extract (40×). (H) Treated with 100mg/kg/day ethanol extract 
(40×). 
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Figure 4.11 Photomicrographs of the spleen for control and treated animals. (I) 
Control tissue for aqueous extracts (40×). (J) Treated with 10% 
aqueous extract of Asparagus laricinus. (40×). (K)  Control rats for 
ethanol extract (40×). (L) Treated with 200mg/kg/day ethanol extract 
(40×). 
 4.6 Overall summary 
 
Biochemical and haematological tests were selected as indicators of the damage to 
the tissue of organs, including the liver, kidney and spleen. Extremely high or low 
results would then estimate the severity of the damage to such tissues. Histological 
results would demonstrate the type of tissue damage, as well as the extent of the 
damage. 
 
When the combined experimental group (n=42) was compared with the combined 
controls (n=12), no significant difference was observed for the mass and selected 
haematological and biochemical variables.  
© Central University of Technology, Free State
57 
 
 
Further comparison of treatment groups (n=6) and controls (n=6) across all ethanol 
extracts showed significant differences in the starting median change in weight at the 
200g/kg/day dosage, as well as the median termination weight at 400g/kg/day. The 
median change in weight remained slightly below 50g over the entire two-week period 
of experimentation. A significant difference (p<0.05) was observed for platelets with 
the ethanol extract at a dose of 50g/kg/day. There were no statistical differences 
between the treatment groups and controls with regard to the rest of haematological 
variables and selected biochemical tests. 
 
Comparison of the controls (n=6) and treatment groups (n=6) revealed an average 
median change in weight of slightly above 50g over the entire eight-week period of 
experimentation with aqueous extracts. A significant difference (p<0.05) was observed 
for both haemoglobin and BUN results with the 20% water extract. There were no 
statistical differences between the treatment and control groups with regard to the rest 
of haematological variables and selected biochemical tests. 
 
Histological evaluation could not reveal any pathological changes in both the aqueous 
and ethanolic extracts across all levels of dosage. 
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CHAPTER 5 
 
DISCUSSION 
 5.1 Introduction 
 
One of the unique aspects attributed to planet earth is plants. A variety of plant species 
have been scientifically and traditionally identified for their medicinal properties and 
values respectively. Accessibility and affordability have always made traditional 
medicine convenient for healthcare and nutritional use in Africa (World Health 
Organization., 2002; Tchacondo et al., 2012). 
 
The family/genus asparageceae has also been used for treatment of various ailments. 
The species Asparagus laricinus has been extensively studied for its anticarcinogenic 
properties (Mashele & Konesnikova, 2010), and the active ingredients identified (Fuku 
et al., 2013). The accumulated rich knowledge of this species have encouraged us to 
continue with further studies in the form of in vivo assessment of the toxicology of both 
aqueous and ethanolic extracts of the plant. 
 
Although medicinal plants may have biological activities that are beneficial to humans, 
the potential toxicity of these bioactive substances has not been well established 
(Rosidah et al., 2009; Idoh et al., 2016). Moreover, despite the widespread use, few 
scientific studies have been undertaken to ascertain the safety and efficacy of 
traditional remedies (Graça et al., 2007). 
 
The main purpose of the study was to establish whether Asparagus laricinus has any 
toxic or adverse effects on the tissue and organs of animal models (Sprague Dawley 
rats). This was done by administering both aqueous and ethanol extracts of Asparagus 
laricinus to groups of animals, and also varying the concentrations of these extracts. 
Dose-response assessment of the effect of the extract was done by analysis of the 
blood samples collected at the end of the research. Haematological analysis consisted 
of a full blood count; clinical chemistry analysis was done by measuring selected liver 
enzymes; creatinine and urea for renal function; and histologically we investigated any 
damage or inflammation of the liver, spleen and kidney tissue.  
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 5.2 Comparison of haematological parameter of control and different concentration of all extracts 
 
Full blood count results could not point in the direction of toxicity, adverse effects or 
hazards, as indicated by statistically similar results between the exposed and 
unexposed groups, using both aqueous and ethanol extracts at different 
concentrations. However, as indicated in Table 4.6 in chapter 4, significant differences 
were noted with ethanolic extracts for platelets at a dose of 50mg/kg/day (p=0.011). It 
must be noted that this statistical significant change produced a 15% increase in the 
median concentration, in comparison with the control. Although it seems significant, it 
must be noted that the reference range for platelets in humans spans 63%, and the 
400mg/kg/day group showed a 13% increase without a statistically significant change.  
 
Based on the above, it seems that even though a statistical significant change was 
obtained, it does not translate to a clinically significant change. 
In the aqueous extracts, statistically significant results were observed for 20% of the 
extracts for Hb, as indicated in Table 4.10. This increase in the haemoglobin 
concentration produced a 5% change, while the human range spans 37% and the 10% 
aqueous extracts had a 6% change without a statistical significant change. Based on 
these facts it seems that the statistical significant change does not translate to a 
clinically significant change. 
 5.3 Comparison of chemical parameter of control and different concentration of all extracts 
 
Generally, biochemical results  could not conclusively indicate the presence of toxicity, 
as the majority of the results were not significantly different in both the treated and 
untreated groups of rats.  Table 4.10, however, paints a different picture, as it shows 
significant differences between the controls and rats exposed to 20% aqueous extracts, 
with regard to the BUN. The results show no specific trend or pattern, and therefore 
may mislead the researcher. The results might be genuine or spurious, and therefore 
further investigations may be suggested. 
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5.4 Comparison of histological changes between control and different concentration of all extracts 
 
There were no traces of damage or inflammation of the tissue excised from the kidney, 
liver and spleen of the rats exposed or unexposed to Asparagus laricinus extracts. 
Figures 4.9 to 4.11 compare haematoxilyn and eosin stains (H&E) from both exposed 
and unexposed tissue. 
 
Literature does not reveal any toxicological studies on Asparagus laricinus, however, 
similar studies were conducted for anticancer plants using either mice, rats or rabbits. 
There are reports on acute toxicity studies on Hyptis suaveolens Poit. (Lamiaceae) 
leaves (Danmalam et al., 2009); Moringa oleifera Lam. (Moringaceae) (leaves) (Isitua 
& Ibe, 2003; Sreelata et al., 2011; Ugwu et al., 2013; Berkovich et al., 2013); 
Newbbouldia laevis (Bignoniaceae) (stem leaves and roots) (Azuine et al., 1995) and 
Nigella sativa (Ranunculaceae) (seeds) ( Ali & Blunden, 2003; Ekanen & Yusuf, 2008;) 
to cite but a few. 
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CHAPTER 6 
CONCLUSION AND RECOMMENDATIONS 6.1 Introduction 
 
The main purpose of the study was to assess the safe use of the Asparagus laricinus 
plant extracts by undertaking toxicological studies. This was done by evaluating 
hepatotoxicity, nephrotoxicity, spleen and vascular damage to the animals. Selected 
liver enzymes and other tests; renal dysfunction indicators and haematological 
parameters were investigated by statistically comparing treated and untreated animals. 
Furthermore, the excised liver, spleen and kidney tissue were examined histologically 
for any damage or inflammation caused by exposure to the extracts. 
 6.2 Conclusion 
 6.2.1 Haematological parameter 
 
There was no significant difference between the treatment and control groups with 
regard to the full blood count.There were, however, clinically non-significant changes 
that can be deemed as sporadic or anomalic results, regarding the haemoglobin levels 
while using 20% aqueous extracts, and with regard to platelets while using ethanolic 
extracts administered at 50mg/kg/day. The results could not demonstrate any specific 
pattern across the aqueous or ethanol extracts. 
 6.2.2 Clinical chemistry parameters 
 
There was no significant difference between the treatment and control groups with 
respect to the liver enzymes, blood urea nitrogen, cholesterol and creatinine results. 
There were, however, sporadic or anomalic results regarding BUN, while using 20% 
aqueous extracts., The fact that the results could not demonstrate any specific pattern 
or trend across varying concentrations warrants further investigation.  
 6.2.3 Histological changes 
 
The histological assessment has proven that both aqueous and ethanolic extracts of 
Asparagus laricinus had no detrimental or adverse effects on the vital organs of the 
Sprague Dawley rats. Tissue damage, lesions or inflammation were not observed on 
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the kidney, liver or spleen of the treatment groups as compared to the control group. 
The pattern was observed across increasing doses of aqueous and ethanolic extracts. 
 6.3 Limitations 
 
Although the collection and analysis of blood and tissue samples needs ample time, 
the actual experimental time was conducted over a maximum period of eight weeks, 
which perhaps was not sufficient for the tissue damage to occur. The number of rats 
was limited as a result of the of laws and policies governing the use of experimental 
animals for research purposes. We currently do not have the reference or normal 
ranges for biochemical and haematological parameters for rats, and therefore relied 
on comparing the results to those of the control group. 
 6.4 Recommendations 
 
The period of experimentation should be increased and motivation for a bigger sample 
size would also be necessary, for the researcher to improve the quality of the results. 
Normal ranges for the haematological and biochemical tests should be established. 
 6.5 Overall conclusion 
 
In conclusion, we summarize that the toxicological evaluation of Asparagus laricinus 
extracts may be considered relatively free of toxicity when given orally, as it did not 
cause death, damage or inflammation to the tissues, nor produced any remarkable 
biochemical and haematological adverse effects in both the male and female Sprague 
Dawley rats. Further studies may also be conducted to demonstrate in vivo efficacy 
against cancer, because thus far studies were conducted using cell lines (in vitro 
studies). 
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